PDCD1 and neoplasm: Immune checkpoint inhibitors (ICIs) are monoclonal antibodies targeting checkpoint proteins expressed by immune cells or tumor cells, such as cytotoxic T lymphocyte–antigen 4 (CTLA-4), programmed cell death protein 1(PD-1), and PD-ligand 1 (PD-L1).